Angiosarcoma (2026): Symptoms, Types, Diagnosis & Treatment Options

Angiosarcoma is one of the rarer cancers a person can be diagnosed with rare enough that many general practitioners will never see a case in their career, and rare enough that a lot of what’s published online about it is either too generic to be useful or too alarming to be helpful. This guide is written to sit in between: medically precise about what angiosarcoma actually is and how it’s treated, honest about the fact that outcomes vary enormously by where it starts, and clear about what questions to bring to a specialist.

What Is Angiosarcoma?

Angiosarcoma is a rare, aggressive cancer that develops from endothelial cells — the cells that line the inside of blood vessels and lymphatic vessels. It can arise almost anywhere in the body, but most commonly appears in the skin (particularly the scalp and face in older adults), the breast, the liver, or, less commonly, the heart. Symptoms and appearance depend entirely on where the tumor develops — a skin lesion looks nothing like a liver tumor’s presentation. Diagnosis requires imaging and biopsy with specialist pathology confirmation. Treatment is built around surgery where the tumor is removable, often combined with radiation and sometimes chemotherapy, and outcomes vary substantially depending on tumor site, size, and whether it has spread.

Because angiosarcoma is rare and can arise in very different organs, diagnosis and treatment should be planned by a multidisciplinary oncology team experienced with sarcomas and the specific tumor location involved — not treated as a single, interchangeable disease.

What Makes Angiosarcoma Different

Angiosarcoma is a type of soft-tissue sarcoma cancer of connective tissue — that specifically originates from vessel-lining cells, distinguishing it from carcinomas (which arise from organ-lining epithelial cells) and from benign vascular growths like hemangiomas, which don’t invade surrounding tissue or spread. It accounts for only about 1–2% of all soft-tissue sarcomas, and soft-tissue sarcomas themselves are uncommon cancers which is why angiosarcoma is estimated at roughly 1 case per million people annually in some population studies.

This rarity has two practical consequences worth understanding early: general oncologists may have limited direct experience with it, and published outcome data often comes from small patient cohorts rather than the large trials available for common cancers. Both are reasons specialist, sarcoma-experienced care matters more here than for many other diagnoses.

Types of Angiosarcoma by Site

It’s worth being precise about the associations here: prior radiation or chronic lymphedema are recognized risk factors for specific angiosarcoma subtypes, but the overwhelming majority of people who receive radiation therapy or develop lymphedema never go on to develop angiosarcoma. These are documented associations in a rare subset of cases, not a common outcome.

Cutaneous Angiosarcoma

The most common form, cutaneous angiosarcoma typically appears as:

• Small reddish or bluish lumps, often on the scalp or face in older adults
• A bruise-like patch that doesn’t fade and may slowly enlarge
• Skin that becomes swollen, thickened, or nodular in the affected area
• Bleeding or ulceration as the lesion progresses

Early cutaneous angiosarcoma can genuinely resemble a bruise, a benign vascular lesion, or a rash — which is part of why diagnosis is sometimes delayed. A skin change that persists beyond what’s expected for a bruise, continues to enlarge, or bleeds without clear cause warrants professional evaluation. Appearance alone cannot confirm or rule out the diagnosis — that requires biopsy.

Breast Angiosarcoma

Breast angiosarcoma can occur as a primary tumor (arising without a prior cause) or, more commonly in clinical experience, as a secondary tumor following previous radiation therapy for breast cancer or chronic lymphedema in the arm.

Possible symptoms include:

• A breast lump
• Swelling or enlargement of the breast
• Skin discoloration — often described as a purple, bruise-like patch
• Skin thickening
• Pain in some cases, though many cases are not initially painful

A breast lump is far more commonly caused by benign conditions or more common breast cancer types — angiosarcoma is a rare cause. That said, any new or persistent breast change deserves prompt evaluation regardless of the eventual diagnosis.

Visceral (Internal Organ) Angiosarcoma

Internal-organ angiosarcomas are rarer still and tend to present with vaguer, more nonspecific symptoms, which is one reason they’re sometimes diagnosed at a more advanced stage.

Hepatic (Liver) Angiosarcoma

Possible symptoms:

• Abdominal discomfort or pain
• Fatigue
• Unexplained weight loss
• An enlarged liver on examination
• Unexplained bleeding or anemia
• Jaundice in some cases

Cardiac Angiosarcoma

Because cardiac angiosarcoma most often develops in the right atrium, it can interfere with normal blood flow through the heart. Possible symptoms:

• Shortness of breath — often the most frequently reported symptom
• Chest discomfort
• Irregular heartbeat (arrhythmia)
• Symptoms of heart failure
• Swelling in the abdomen, legs, or ankles, and distended neck veins, if blood flow is obstructed
• Fluid around the heart (pericardial effusion)

These symptoms are nonspecific and are far more commonly caused by other cardiac or hepatic conditions. They warrant medical investigation, not a jump to the conclusion of angiosarcoma — but they shouldn’t be dismissed either, particularly if they’re persistent and unexplained.

General Symptoms and When to Seek Evaluation

Because presentation varies so much by site, there’s no single universal angiosarcoma symptom — but across all forms, these patterns are worth professional evaluation:

• A skin lesion, bruise-like patch, or lump that persists, enlarges, or bleeds without clear explanation
• Unexplained, persistent swelling in any area
• A growing lump anywhere in soft tissue
• Unexplained abdominal pain, enlargement, or persistent fatigue
• Unexplained weight loss
• Cardiac or respiratory symptoms that don’t resolve with standard treatment

These signs do not mean a person has angiosarcoma — each is far more commonly caused by benign or unrelated conditions. But persistent, unexplained, or progressively worsening changes deserve a medical evaluation rather than a wait-and-see approach.

What Causes Angiosarcoma?

For most cases, there is no single identifiable cause. Angiosarcoma often arises without any known trigger. Where associations have been established through research, they include:

• Prior radiation therapy — a recognized but uncommon late complication, sometimes appearing many years after treatment for an unrelated earlier cancer
• Chronic lymphedema — longstanding swelling from lymphatic dysfunction is associated with a rare angiosarcoma subtype
• Certain chemical/occupational exposures — established for specific rare exposures in some hepatic angiosarcoma cases, though this is not a common pathway
• Inherited genetic syndromes in a minority of cases — including BRCA1/BRCA2 mutations and conditions like neurofibromatosis, Maffucci syndrome, or Klippel-Trenaunay syndrome
• Foreign material (such as certain implants) in rare documented cases

None of these factors mean angiosarcoma is preventable in any reliable sense — most people with these risk factors never develop it, and most people who develop angiosarcoma have none of these identifiable factors. Awareness of new or changing symptoms, rather than a screening program, is the realistic and evidence-supported approach for most people.

How Is Angiosarcoma Diagnosed?

The diagnostic pathway generally follows: clinical assessment → imaging → biopsy → histopathology → immunohistochemistry → staging.

Clinical assessment. Depending on the suspected site, this might involve a dermatologist, surgical oncologist, sarcoma specialist, breast specialist, hepatobiliary specialist, or cardiologist.

Imaging. Selected based on tumor location — potentially ultrasound, CT, MRI, PET/CT, mammography, echocardiography, or cardiac MRI/CT. Not every patient needs every scan; imaging choice follows the suspected primary site.

Biopsy. Tissue sampling is essential to confirm the diagnosis — imaging alone cannot distinguish angiosarcoma from other vascular lesions or tumors with confidence. Biopsy approach depends on tumor accessibility and location.

Pathology and Immunohistochemistry

Angiosarcoma can sometimes be genuinely difficult to distinguish from other vascular lesions or tumor types under the microscope, which makes specialist pathology review particularly important for this diagnosis.

Pathologists often use immunohistochemistry — staining tissue for specific markers — to confirm endothelial (vessel-lining) origin. Markers commonly used include:

• CD31
• CD34
• ERG
• FLI1

A single positive marker does not, by itself, confirm angiosarcoma. Interpretation requires the full pathology picture — tissue architecture, cell appearance, and the complete marker panel together, reviewed by a pathologist experienced with vascular tumors.

Staging

Staging accounts for tumor size, local invasion, lymph node involvement where relevant, and distant metastasis — the same broad TNM principles used across cancers. However, sarcoma staging systems can differ meaningfully from the staging used for carcinomas, and staging specifics vary depending on the primary tumor site. There is no single universal “angiosarcoma stage” table that applies identically regardless of where the tumor originated.

Angiosarcoma Treatment Options

There is no single treatment for angiosarcoma. Management depends on the tumor’s site, size, whether it’s surgically resectable, stage, any prior treatment, whether the disease is metastatic, and the patient’s overall health.

Surgery

Where feasible, surgical removal — often wide local excision to achieve clear margins — offers the best chance at local control in localized disease. Depending on the site, this may involve reconstruction (particularly for cutaneous or breast cases) or organ-specific surgery (such as liver resection for hepatic angiosarcoma). Surgery never guarantees complete removal or cure, particularly given angiosarcoma’s tendency toward local infiltration.

Radiation Therapy

Often used after surgery to help control microscopic residual disease, or as a primary local-control approach for selected unresectable or recurrent tumors. For cutaneous angiosarcoma specifically, combining radiation with weekly paclitaxel chemotherapy has shown benefit for local control in retrospective studies.

Chemotherapy

Systemic chemotherapy is commonly used, particularly for advanced, unresectable, or metastatic disease. Anthracycline-based regimens are typically a first-line approach for soft-tissue sarcomas generally, with paclitaxel showing particular benefit in cutaneous angiosarcoma. Regimen selection is highly individualized and should be discussed directly with your treating oncologist — no single regimen is universally appropriate.

Targeted Therapy and Immunotherapy

Targeted therapies and immune checkpoint inhibitors are being explored for angiosarcoma, particularly in metastatic disease, though this remains an evolving area rather than an established universal standard. Molecular characteristics of the tumor may inform whether these options are relevant to your specific case.

Clinical Trials

Because angiosarcoma is rare and treatment evidence is still developing, clinical trials represent a meaningful part of the treatment landscape, particularly for advanced or metastatic disease. Ask your oncology team directly whether relevant trials are available.

Treatment by Disease Setting

This is a general framework, not an individual treatment recommendation — your specific plan depends on factors this table cannot capture.

Metastatic Angiosarcoma

Angiosarcoma most commonly spreads to the lungs, and sometimes to the liver, brain, bones, or other sites depending on the primary tumor location. A metastatic diagnosis does not automatically mean treatment is no longer possible — it means treatment goals typically shift toward disease control, symptom management, and quality of life, using systemic therapy, selected local treatments for accessible metastases, clinical trials, and supportive care.

It’s worth being clear about the distinction between disease control (slowing or stabilizing growth), symptom control (managing the effects of the disease), and cure (complete, lasting eradication) — these are different, legitimate treatment goals, and which one applies to your situation should be discussed explicitly with your oncology team.

Is Angiosarcoma Curable?

For localized disease where complete surgical removal is achievable, cure is possible in some cases. However, angiosarcoma’s tendency toward local recurrence and its capacity to spread — even after apparently complete initial treatment — means outcomes vary substantially and depend on:

• Tumor site (superficial cutaneous disease generally has a more favorable course than deep-seated or visceral disease)
• Tumor size (larger tumors, particularly over 5cm, are associated with worse outcomes)
• Margin status after surgery
• Presence of distant metastasis at diagnosis
• Response to treatment

No oncologist can honestly promise cure for angiosarcoma. What a specialist team can offer is a treatment plan targeted at the best achievable outcome for your specific tumor characteristics.

Prognosis and Survival — Why One Number Doesn’t Apply

Angiosarcoma prognosis varies more dramatically by site than almost any other single factor. Published data illustrates this well: one 21-year single-center study of 128 angiosarcoma patients found a median overall survival of 20 months and a 5-year overall survival of roughly 30%, but outcomes differed substantially by subtype — superficial (cutaneous) cases had meaningfully better outcomes than deep-seated or visceral disease, and tumors larger than 5cm or with distant metastasis at diagnosis predicted worse outcomes.

Overall five-year survival figures across all angiosarcoma types cited in patient-facing sources range from roughly 24% to 38%, reflecting differences in patient populations and time periods studied rather than a single “true” number. For context on how much site matters: one systematic review of hepatic angiosarcoma specifically found a median survival of just 7 months, improving to roughly 17 months with surgical resection — figures dramatically different from cutaneous disease survival data.

These are population-level statistics from specific published studies, not a prediction for any individual patient. Ask your oncology team what data is most relevant to your specific tumor site, size, and stage — a hepatic angiosarcoma statistic tells you almost nothing about a cutaneous case, and vice versa.

Follow-Up After Treatment

Because recurrence and delayed metastasis are recognized patterns in angiosarcoma, long-term surveillance is standard practice. This typically includes regular clinical examinations, site-specific imaging at intervals your team will determine, and monitoring for both local recurrence and distant spread — most commonly to the lungs. There’s no single universal follow-up schedule; intervals are individualized based on your specific risk factors and how much time has passed since treatment.

Angiosarcoma Treatment in India

International patients researching angiosarcoma treatment in India should prioritize centers with genuine sarcoma-specific multidisciplinary infrastructure — this matters more for angiosarcoma than for common cancers, given how much management depends on coordinated input across surgical oncology, radiation oncology, pathology, and, depending on the tumor site, cardiology or hepatobiliary surgery. Relevant capabilities to ask about include:

• A dedicated sarcoma unit or multidisciplinary tumor board with documented angiosarcoma experience specifically, not just general oncology volume
• Pathology teams experienced with immunohistochemistry-based confirmation of vascular tumors
• Site-specific surgical expertise (limb-sparing surgery, hepatobiliary surgery, or cardiac surgery, depending on tumor location)
• Radiation oncology with modern planning technology (IMRT or similar)
• Reconstructive surgery capability where relevant

Several major Indian cancer centers — including Tata Memorial Hospital, AIIMS, and Apollo Cancer Centres — maintain dedicated sarcoma units. We don’t claim any specific hospital is “the best” for angiosarcoma without current, verifiable outcomes data specific to this rare tumor, and we’d encourage the same skepticism toward any page that ranks “top clinics” for angiosarcoma without disclosing a transparent, evidence-based methodology.

Angiosarcoma Treatment Cost in India

There’s no universal angiosarcoma treatment price, and given how rare this cancer is, no reliable angiosarcoma-specific package pricing exists publicly — every published source quotes generic “soft-tissue sarcoma treatment” ranges, not figures specific to angiosarcoma’s frequently more complex, multi-site management.

Published domestic sarcoma treatment ranges cluster around $2,200–$12,000, but these figures typically reflect baseline domestic pricing for more straightforward, localized soft-tissue sarcoma cases — not the full scope of international-patient coordination, nor the added complexity that hepatic or cardiac angiosarcoma cases often involve.

These are component ranges, not a package quote, and an accurate estimate absolutely requires your specific medical records reviewed by a treating team — angiosarcoma’s site-dependent complexity makes a generic number particularly unreliable for this diagnosis. Treat any source offering one confident “angiosarcoma treatment cost” figure with real skepticism.

The International Patient Journey

1. Medical record and pathology review — send existing imaging, biopsy reports, and pathology slides for specialist review, ideally including immunohistochemistry results if already performed
2. Specialist consultation — sarcoma oncology, and depending on site, hepatobiliary or cardiac specialist input
3. Treatment plan and case-specific cost estimate
4. Hospital coordination and medical visa support
5. Travel and pre-treatment workup
6. Treatment — surgery, radiation, chemotherapy, or a combination, per your specific plan
7. Recovery and discharge
8. Long-term remote follow-up coordination, given the importance of extended surveillance for this disease

We coordinate each of these steps, but we don’t and can’t promise treatment success, cure, visa approval, or fixed final pricing before your case has been medically evaluated.

Common Misconceptions

How Shifam Health Can Help

Angiosarcoma’s rarity means general cancer information rarely maps cleanly onto your specific situation — a cutaneous case and a hepatic case are genuinely different diseases in practice, even sharing the same name. We help connect you with sarcoma-experienced oncology teams matched to your tumor’s specific site, coordinate pathology and imaging review before you travel, and build a treatment estimate around your actual case rather than a generic sarcoma-cost page.

Reach out on WhatsApp or submit a quick inquiry — our team responds within 24 hours, with no obligation to proceed.

Frequently Asked Questions

People Ask Further